What the market pause in IPOs means

July 29, 2022

There is a pause in IPOs - so what?

The public capital markets have faced a series of onslaughts in the first half of 2022 that have left it lingering in a state of high volatility. With the uncertainty of the public markets looming and valuations dropping (some would say right-setting), many companies have understandably developed cold feet over proceeding with their long awaited IPOs. 

In the first six months of 2022, only 92 companies went public in the USA and 100+ companies withdrew their intent to launch an IPO. The global markets saw IPO volumes decrease by 46%, and if the markets continue at this pace for the remainder of the year, this would result in a projected YoY decrease of almost 83%. 

With the public markets being hard hit, the private capital markets have experienced some interesting trends.

While some segments of private capital have experienced a decline, others are proving to be insulated from the storm and, in fact, seem to be outpacing previous years’ investment. 

Venture Capital and other Institutional investing are both also experiencing a sizeable decline in 2022. According to CB Insights, global funding to startups experienced a QoQ drop of 23% with $108.5B being invested. While the amount invested is significant, it still represents the largest quarterly percentage drop in funding in nearly a decade. Funding from the VC’s is seeing the majority go to early-stage startups (64%) with only 13% and 11% going to mid and late stage respectively. 

This trend suggests that VC’s are focusing on the long-term play and what they believe will yield them best results when the market settles, placing mid-to-late-stage companies between a rock and a hard place. Caught in a void where they seemingly aren’t attractive enough to VC and a volatile market which will not produce a successful IPO launch, mid-to-late stage companies have few avenues to explore to offer some capital and liquidity. Community rounds, or Equity Crowdfunding, can offer a solution to this mid-to-late stage desert. 

Equity crowdfunding (ECF) is a relatively new phenomenon for capital raising within the private markets and it is showing significant trends of insulation from the overarching down market, in fact, it seems to show an upward trajectory while the majority of the markets decrease - which means there is a lot of untapped potential. Since equity crowdfunding became legal for non-accredited investors in 2017 we have seen a significant rise in the Regulation Crowdfunding space with 2021 investments hitting $570M. This represents a compound annual growth rate of more than 11.5% in the five years since 2017 and, with Q1 of 2022 representing one of the largest quarters to date with $133M raised across 1,038 offerings, it shows no signs of slowing. According to research conducted by KingsCrowd, 2022 is seeing amounts on checks being written for crowdfund raises up 40% when compared to the first half of 2021. Their data shows that in June 2022, checks were nearly double the average size in June 2021.

SEC filings for crowdfund raises (Form 1-A and Form C) at the beginning of 2022 are exceeding the pace with the beginning of 2021 - with a 2% year-over-year increase for Q1. 

And again while Q1 outpaced last year for all filings, if you look at the trend for Reg CF raises alone, you'll see only a slight dip from last year projected. There is an appetite to raise and investors are looking for unique ways to diversify.

Bar graph showcasing Reg CF Raises, y-axis is millions of dollars, x-axis is the year, showing increase in raises over the years.
(Source: Forbes, July 25, 2022)

While other sections of the capital markets, especially the public markets and VC, are facing intense turmoil, Regulation A and Regulation CF marketed retail capital offerings remain strong. Companies are displaying high interest in tapping into this unique pool of investors to “test the waters” and raise needed capital to wait out the public market downturn so they can launch an IPO in a strong market.

The trend remains that these markets seem to be insulated from the macro-downturn and volatility, as well as still being attractive to investors that are looking for impact investing alternatives.

Sources: Fast Company, CB Insights, Kingscrowd State of Venture 2022

Please note: The foregoing is market commentary only. Any market participant should do their own research and make informed decisions with their own advisors to make sure the particulars of their capital raise are correct for that particular issuer in that circumstance.

Monogram Case Study - DealMaker (Embed)

When VCs said no, Monogram turned to retail investors. That decision powered their rise from startup to publicly traded company—and even helped them raise an additional $13M privately after their Nasdaq debut.

Monogram at NASDAQ celebration

The Challenge: Raising Capital on Their Terms

The Challenge: Raising on Their Terms

Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.

Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?

  • Control and ownership: Not only were they able to raise the capital they needed to grow the business—they did it on their own terms.
  • Long-term asset: They wanted to build an army of true believers who wanted to see the company succeed and would continue to reinvest over the years.
  • A value-add network: Raising from retail allowed Monogram to amass a waiting list of thousands of patients eager to participate in future trials.
  • Aligned incentives: Their mission to improve patient outcomes and build a better future for those struggling with joint pain resonated with retail investors.

The Power of Retail: Monogram's Capital Journey

Start Date End Date Type Platform Amount Raised # Investors
3/13/193/31/20A+SeedInvest$14,588,6686,000
11/16/201/16/21A+StartEngine$2,965,5018,000
1/17/212/18/22A+StartEngine$23,647,85314,082
7/15/223/16/23CFDealMaker$4,673,0002,249
3/1/234/8/23A+Republic$232,275120
3/1/235/23/23A+DealMaker$15,958,3645,198
5/18/23-Nasdaq listing
7/2410/24Unit OfferingDealMaker$12,990,1032,745

Monogram Capital Raise Timeline

Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.

Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.

$80M+
Raised across seven campaigns
~40,000
Investors championing Monogram's vision
20%
Of each raise came from previous investors

Marketing Excellence

DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.

Premium Publications

Targeted campaigns in premium publications like Morning Brew captured qualified investors

High-Engagement Webinars

Engaging events that generated over $4.3 million in investments

Community Building

Strategic approaches that fostered a loyal shareholder base

Investment Momentum

Innovative approaches that amplified investment momentum

Monogram's Journey to Success

Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:

  • Filed its first patent application in 2017
  • Conducted clinical studies at UCLA and University of Nebraska
  • Expanded the team with key hires
  • Attracted a top-tier advisory board to guide clinical innovations
  • Signed their first distribution partnerships
  • Made headlines with cutting-edge live demonstrations
  • Secured 501(k) FDA clearance for the mBôs surgical system

Nasdaq Debut & Beyond

In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.

For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.

Public perception says you can't raise privately post-IPO. Monogram proved that wrong.

Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.

This was retail capital at its best: strategic, repeatable, and aligned.

One vision. Zero compromises.

This wasn't a one-time raise. It was a multi-year capital strategy.

Retail capital helped Monogram:

  • Go from concept to commercialization without relying on VCs
  • Retain ownership and control in a high-burn industry
  • Build a base of loyal shareholders who invested not once, but over and over again
  • Uplist to the Nasdaq, and still keep raising post-IPO

This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.

Dr. Doug Unis Quote
Ben Sexson Quote

Ready to Raise Capital on Your Terms?

Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.

Explore Raising Capital with DealMaker
DealMaker Logo

The ultimate technology for raising capital online

Talk to the experts
The ultimate technology for raising capital online - talk to the experts